Balancing access and evaluation in the approval of new cancer drugs

JAMA

Volumn 305, Issue 22, 2011, Pages 2345-2346

  Miller, Franklin G ^a   Joffe, Steven ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

CANCER SURVIVAL; DRUG APPROVAL; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK BENEFIT ANALYSIS; UNITED STATES;

EID: 79958047618     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.784     Document Type: Note

References (10)

1. Johnson JR, Ning Y-M, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst. 2011;103(8):636-644.
2. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.
3. Rettig RA, Jacobson PA, Farquhar CM, Aubry WM. False Hope: Bone Marrow Transplantation for Breast Cancer. Oxford, England: Oxford University Press; 2007.
4. Adzick NS, Thom EA, Spong CY, et al; MOMS Investigators. A randomized trial of prenatal vs postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993-1004.
5. Allison M. Can cancer clinical trials be fixed? Nat Biotechnol. 2011;29(1):13-15.
6. Carpenter D. Reputation and Power. Princeton, NJ: Princeton University Press; 2010.
7. Ellenberg SS. Accelerated approval of oncology drugs: can we do better? J Natl Cancer Inst. 2011;103(8):616-617.
8. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med. 2011;364(12):1087-1089.
9. Rawls J. A Theory of Justice. Cambridge, MA: Harvard University Press; 1971.
10. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med. 2011;364(5):476-480.